APOB and metabolic syndrome: LDL-C remains the primary target for lipid-lowering therapy in the management of dyslipidemia in Europe and the United States (6, 25).Analyzing the reasons for this, there is ample evidence that lowering ApoB levels significantly reduces the risk of developing coronary heart disease as well as improves prognosis.